Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A protein-centric glycoproteomic strategy identifies site-specific glycans as robust diagnostic markers for hepatocellular carcinoma

ABSTRACT: In this study, we achieved the quantitative glycoproteomics analysis of a large cohort of clinical specimens including 100 Hepatocellular carcinoma (HCC) and 100 healthy control human serums by using an integrated platform.

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Lei Liu; Ming Liang Ye

PROVIDER: PXD065283 | JPOST Repository | Fri Jun 26 00:00:00 BST 2026

REPOSITORIES: jPOST

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	liulei_OE480_2024HCC_20240428_MSQC.raw	Raw
	liulei_OE480_2024HCC_20240429_MSQC.raw	Raw
	liulei_OE480_2024HCC_20240430_MSQC.raw	Raw
	liulei_OE480_2024HCC_20240501_MSQC.raw	Raw
	liulei_OE480_2024HCC_20240502_MSQC.raw	Raw

Items per page:

1 - 5 of 20

Publications

A Protein-Centric Strategy Coupled with Match-Between-Run Glycoproteomics Enables Discovery of Robust Site-Specific Glycan Biomarkers for Hepatocellular Carcinoma.

Liu Lei L Ma Taiheng T Liu Qi Q Zhu He H Fang Zheng Z Ma Jiahong J Yu Ting T Wang Yan Y Zhou Jiahua J Liu Xiaoyan X Li Yaqian Y Guo Zhimou Z Liang Xinmiao X Dong Mingming M Sun Deguang D Ye Mingliang M

Advanced science (Weinheim, Baden-Wurttemberg, Germany) 20260212 22

Dysregulated protein glycosylation is a hallmark of cancer, and systematic investigation of glycosylation patterns is crucial for identifying biomarkers. However, current glycoproteomic studies are constrained by the limited quantification power of single MS files and focus on dysregulated glycopeptides while neglecting the underlying glycoproteins. To address this, we proposed a protein-centric strategy to prioritize proteins susceptible to aberrant glycosylation, aiming to uncover previously o ...[more]

PMID: 41674345

Similar Datasets

ctDNA methylation markers in diagnosis and prognosis of hepatocellular carcinoma

Project description:To develop diagnostic and prognostic biomarkers, we compared methylation profiles of HCC tissues and normal blood by analyzing 485,000 CpG markers and identified a HCC enriched methylation marker panel compared to that of normal blood. We found there was a highly correlation of methylation profiles between DNA from HCC cancer tissue and matched plasma ctDNA within the same patient. We then selected 10 markers from this panel and created a combined diagnosis score (cd-score) which showed high diagnostic specificity and sensitivity in both a training cohort and an independent validation cohort. We also showed the cd-score correlate highly with tumor load, treatment response and stage and is superior to that by AFP. We also showed the cd-score correlate highly with tumor load, treatment response and stage and is superior to that by AFP. Additional, we generated 8 markers from unicox and LASSO-cox analysis and created a combined prognosis score (cp-score) which could predict prognosis and survival. Together, these findings demonstrated the utility of ctDNA methylation markers in the diagnosis, treatment evaluation and prognosis of HCC.

2019-01-01 | GSE93203 | GEO

Identification of microRNAs specifically expressed in HCV-associated hepatocellular carcinoma

Project description:Background: Several studies have investigated the association of miRNAs with hepatocellular carcinoma (HCC) but the data are not univocal. Methods: We performed a microarray study of miRNAs in hepatitis C virus (HCV)-associated HCC and other liver diseases and healthy conditions. Results and Conclusions: The simultaneous comparison of different liver diseases and normal livers allowed the identification of 18 miRNAs exclusively expressed in HCV-associated HCC, with sensitivity and specificity values of diagnostic-grade. A total number of 76 liver specimens obtained from 43 patients were analyzed: 26 liver specimens obtained from 10 patients with HCV-associated HCC, including 9 specimens from the tumor area (HCC) and 17 specimens from the surrounding non-tumorous tissue affected by cirrhosis (HCC-CIR); 18 specimens from 10 patients with HCV-associated cirrhosis without HCC (CIR); 13 specimens from 4 patients with HBV-associated acute liver failure (ALF); 12 specimens from 12 liver donors (LD); and 7 from normal liver of 7 subjects who underwent hepatic resection for liver angioma (NL).

2013-02-20 | E-GEOD-40744 | biostudies-arrayexpress

Human hepatocellular carcinoma: primary tumor vs.lung metastasis

Project description:microRNA exprssion profiling of HCC comparing primary tumor with lung metastasis. To explore differentially expressed microRNAs involved in process of HCC metastasis, and identify their biological functions. Two-condition experiment, primary tumor specimens vs. lung metastasis specimens. Biological replicates: 3 primary tumor replicates, 3 lung metastatic replicates. One replicate per array.

2012-01-24 | E-GEOD-26323 | biostudies-arrayexpress

Chip-chip from Hepatocellular carcinoma (HCC) specimens with H3K4me3

Project description:Epigenetic changes commonly occur in hepatocellular carcinoma (HCC) and are associated with aberrant gene expression. Recently, we demonstrated the pivotal role of abnormal H3K4me3 methylation, which is catalyzed by the menin/MLL, a TrxG family, in HCC development. Meanwhile, there is clear evidence that increasing global levels of H3K27me3 are activated in human primary HCC. To further elucidate the functional relatedness of the active H3K4me3 and repressive H3K27me3 histone remodeling in HCC, we performed H3K4me3 and H3K27me3 ChIP-on-chip screen using three HCC specimens and their adjacent tissues. Comparison of ChIP-on-chip results between tumor(C) and adjacent tissues(N) from three HCC specimens with H3K4me3

2013-11-08 | E-GEOD-52190 | biostudies-arrayexpress

Chip-chip from Hepatocellular carcinoma (HCC) specimens with H3K27me3

Project description:Epigenetic changes commonly occur in hepatocellular carcinoma (HCC) and are associated with aberrant gene expression. Recently, we demonstrated the pivotal role of abnormal H3K4me3 methylation, which is catalyzed by the menin/MLL, a TrxG family, in HCC development. Meanwhile, there is clear evidence that increasing global levels of H3K27me3 are activated in human primary HCC. To further elucidate the functional relatedness of the repressive H3K27me3 and active H3K4me3 histone remodeling in HCC, we performed H3K27me3 and H3K4me3 ChIP-on-chip screen using three HCC specimens and their adjacent tissues. Comparison of ChIP-on-chip results between tumor(C) and adjacent tissues(N) from three HCC specimens with H3K27me3

2013-11-13 | E-GEOD-52301 | biostudies-arrayexpress

Proteome Landscape of Early Stage Hepatocellular Carcinoma Identifies Proteomic Subtypes and New Therapeutic Targets

Project description:Hepatocellular carcinoma (HCC) accounts for approximately 90% of primary liver cancers, the second leading cause of cancer mortality worldwide. Although HCC surgical treatment may be curative in the early stages, its five-year overall survival is only 50-70%. Advances in proteomic technologies have expanded the breadth and depth of cancer proteome characterization. Here, we present the largest characterization effort on proteomic profiling of 222 tumor and paired non-tumor tissues in clinically early HCC (Barcelona Clinic Liver Cancer (BCLC) stage 0 and A). Quantitative proteomic data identified three more-refined subtypes in the early- stage cohort of HCC (termed S-I, S-II and S-III) with different clinical outcomes. S-I retained hepatic detoxification and metabolic functions with the best prognosis, S-II increased molecular expression related to proliferation, and S-III showed distinct enrichment of tumor metastasis and immune response pathways and the poorest prognosis. The subtype specific signatures targeted by known FDA approved drugs or inhibitors under clinical investigations for HCC provide a novel resource for HCC therapeutic targets. A new mechanism of disrupted cholesterol homeostasis with aberrant accumulation of cholesteryl esters was also highlighted in S-III. Thus, this study represents the first proteomic stratification of early-stage HCC, providing insights into tumor biology and personalized targeted therapy.

2019-05-29 | PXD006512 | Pride

Site-specific N-glycoproteomic analysis of Intrahepatic cholangiocarcinoma and Hepatocellular carcinoma

Project description:In this study,we performed integrated glycoproteomic and global proteomic analysis of tumor tissues of ICC and HCC to investigate the differences in site-specific glycosylation and proteins between ICC and HCC tumors. The paired paracancer tissue were also included as controls to determine the site-specific glycosylation changes in ICC and HCC tumors. The alteration extents in glycopeptide, global proteome, and normalized glycosylation in different sample groups were systematically compared.

2022-08-11 | PXD020277 | Pride

Proteome Landscape of Early Stage Hepatocellular Carcinoma Identifies Proteomic Subtypes and New Therapeutic Targets - Phosphorylation data

2019-03-01 | PXD008373 | Pride

Gene expression profiling of hepatitis B- and hepatitis C-related hepatocellular carcinoma using graphical Gaussian modeling

Project description:Gene expression profiling of hepatocellular carcinoma (HCC) and background liver has been studied extensively; however, the relationship between the gene expression profiles of different lesions has not been assessed. We examined the expression profiles of 34 HCC specimens (17 hepatitis B virus [HBV]-related and 17 hepatitis C virus [HCV]-related) and 71 non-tumor liver specimens (36 chronic hepatitis B [CH-B] and 35 chronic hepatitis C [CH-C]) using an in-house cDNA microarray consisting of liver-predominant genes. Graphical Gaussian modeling (GGM) was applied to elucidate the interactions of gene clusters among the HCC and non-tumor lesions. Gene expression profiling of HCC and non-tumor lesions revealed the predisposing changes of gene expression in HCC. This approach has potential for the early diagnosis and possible prevention of HCC. We examined the expression profiles of 34 HCC specimens (17 hepatitis B virus [HBV]-related and 17 hepatitis C virus [HCV]-related) and 71 non-tumor liver specimens (36 chronic hepatitis B [CH-B] and 35 chronic hepatitis C [CH-C]) using an in-house cDNA microarray consisting of liver-predominant genes. Graphical Gaussian modeling (GGM) was applied to elucidate the interactions of gene clusters among the HCC and non-tumor lesions.

2013-11-14 | E-GEOD-44074 | biostudies-arrayexpress

Glycoproteomic probes for fluorescent imaging of fucosylated glycans in vivo.

Project description: Not available

| S-EPMC1567886 | biostudies-literature